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Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort 
studies in the United Kingdom and Denmark 
 
Dear Editor,  
The pathogeneses of skin diseases are not fully understood. Psychological stress has been 
proposed to be associated with skin diseases, but the epidemiological evidence is limited [1, 
2]. We have recently reported the associations between partner bereavement (an extreme life 
stressor) and psoriasis, atopic eczema and melanoma [3, 4]. In this study, we further 
investigated whether partner bereavement was associated with urticaria, alopecia areata, or 
vitiligo. 
 
We conducted two cohort studies using data from the UK (1997-2017) and Denmark (1997-
2016). In the UK, we used the Clinical Practice Research Datalink Gold to identify partners 
using a previously developed algorithm [3, 4]. In Denmark, we used the data from the Civil 
Registration System to identify partners with an algorithm developed by Statistics Denmark 
[3, 4]. Among eligible couples, we defined bereaved people (exposed) if their partner died 
and matched each with up to 10 non-bereaved partners on age, sex, and, county of residence 
within Denmark, or general practice in the UK on the bereavement date. We followed 
participants from bereavement until the first of: diagnosis of specific outcomes (urticaria, 
alopecia areata, or vitiligo), last data collection from primary care practice (UK), transfer out 
of the practice by either member of the couple (UK), emigration of either member of the 
couple (Denmark), death, or the study end. We used stratified Cox regression to estimate 
hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome, adjusting for 
participants’ Charlson Comorbidity Index (CCI) [5]. In the fully-adjusted model, we 
additionally adjusted for education duration (Denmark), Index of Multiple Deprivation 
quintile (UK), body mass index (UK) and lifestyle variables (UK). As we hypothesized that 
the effect of bereavement would be most pronounced in the short-term, we further examined 
the associations by time since bereavement (0–30 days, 0–90 days, 0–365 days, and 0–1095 
days for alopecia areata and vitiligo; 0–182 days, 0–365 days, and 0–1095 days for chronic 
urticaria, as its definition required two codes recorded six weeks apart). We stratified the 
main analysis by age, sex, and risk of partner death (deceased partner’s age-adjusted CCI 
score and presence of terminal disease). We conducted analyses separately for the UK and 
Denmark, and combined the main results (from the adjusted models) in Stata using 
DerSimonian and Lairds’ random-effects model.  
 
The overall median follow-up was 4 years in the UK and 6 years in Denmark. The overall 
pooled HRs (adjusted for participants’ CCI scores) for associations between partner 
bereavement and chronic urticaria, alopecia areata, and vitiligo were 0.95 (95% CI, 0.85–1.07), 
0.90 (95% CI, 0.73–1.12) and 0.90 (95% CI, 0.74–1.10), respectively (Supporting 
information). We found similar results for chronic urticaria in analyses by time since 
bereavement (Table 1). Event rates for alopecia areata and vitiligo were low, specifically in 
early time periods. Similar results were seen in fully adjusted models (Table 1). For subgroup 
analyses, some evidence suggested that the HR for vitiligo differed by sex (lower HR among 
men) in the UK. No substantial differences were observed across other subgroups for other 
outcomes. 
  
This study investigated associations between partner bereavement and chronic urticaria, 
alopecia areata, and vitiligo in population-based cohorts in settings with universal healthcare 
(UK and Denmark), using harmonised methodology. Previous studies have been limited by 
small sample size, difficulty in measuring stress, and potential misclassification of adverse 
life events due to recall bias [6-8]. We undertook our study in two similar cohorts enabling 
replication, and used partner bereavement as a proxy for acute severe stress with specific 
onset date. Limitations include a lack of information on the level and duration of stress 
arising from bereavement, individual responses to bereavement, social support, potential 
misclassification of partnership status, possible delay between disease onset and diagnosis, 
overrepresentation of severe cases in the Danish hospital setting, and absence (Denmark) and 
missingness (UK) of body mass index and lifestyle covariates. People with mild skin 
conditions may be less likely to seek medical advice immediately after bereavement, which 
may have led to underestimation during short-term follow-up and an overrepresentation of 
the most severe skin diseases. In conclusion, this large study showed no evidence of 
associations between partner bereavement and chronic urticaria, alopecia areata, or vitiligo. 
Despite a large study population, precision was limited by low event rates for alopecia areata 
and vitiligo, especially in early time periods. 
 
Details of the methods, additional and sensitivity analyses, and discussion of results can be 
found via: https://doi.org/10.17037/PUBS.04656104 
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Bereaved cohort Matched comparators Adjusted HR 
(95% CI)a 
Fully adjusted 
HR (95% CI)b 
Bereaved cohort Matched comparators Adjusted HR 
(95% CI)a 
Fully adjusted 



























269 875,386 2483 7,615,764 0.96 (0.84-1.09) 0.97 (0.85-1.11) 67 2,778,742 646 23,908,253 0.93 (0.72-1.20) 0.92 (0.70-1.20) 
0–182 days c 78,004 c 713,353 0.31 (0.08-1.28) 0.41 (0.10-1.71) c 176,120 c 1,684,577 NA NA 
0–365 days 20 150,221 214 1,376,313 0.88 (0.56-1.40) 0.96 (0.60-1.53) c 345,359 c 3,288,129 0.60 (0.14-2.50) 0.66 (0.16-2.81) 




49 901,811 525 8,087,071 0.81 (0.60-1.10) 0.85 (0.62-1.16) 48 2,793,638 417 24,175,497 1.00 (0.74-1.36) 0.98 (0.71-1.35) 
0–30 days c 13,817 c 129,863 NA NA c 29,816 c 288,053 NA NA 
0–90 days c 40,793 35 384,648 0.24 (0.03-1.74) 0.19 (0.02-1.48) c 88,713 c 856,229 NA NA 
0–365 days 8 155,369 105 1,470,901 0.69 (0.34-1.42) 0.73 (0.35-1.54) c 347,651 c 3,333,059 NA NA 
0–1095 days 26 401,742 247 3,779,874 0.91 (0.60-1.37) 0.91 (0.60-1.40) 16 953,497 129 8,957,716 1.20 (0.71-2.02) 1.14 (0.65-2.00) 
Vitiligo             
Entire 
follow-up 
87 910,002 972 8,215,110 0.84 (0.67-1.05) 0.85 (0.67-1.07) 36 2,793,919 314 24,178,445 1.05 (0.74-1.49) 1.17 (0.82-1.68) 
0–30 days c 13,925 c 131,873 0.63 (0.08-4.83) 0.80 (0.09-7.30) c 29,817 c 288,077 NA NA 
0–90 days 5 41,110 39 390,610 1.32 (0.52-3.37) 1.49 (0.55-4.06) c 88,717 c 856,303 NA NA 
0–365 days 23 156,584 177 1,493,648 1.30 (0.84-2.02) 1.32 (0.83-2.10) c 347,669 c 3,333,348 0.16 (0.02-1.15) 0.22 (0.03-1.65) 
0–1095 days 54 404,936 449 3,838,367 1.18 (0.89-1.57) 1.20 (0.89-1.62) 8 953,555 128 8,958,460 0.59 (0.29-1.21) 0.70 (0.34-1.45) 
Abbreviations: HR, hazard ratio; CI, confidence interval; NA, not applicable  
aAdjusted for Charlson Comorbidity Index scores. 
bComplete-case analysis was used to handle missing data for body mass index, smoking status and alcohol consumption (UK), and education duration (Denmark) in the fully 
adjusted model. Of note, the number of events, and person-years at risk in the bereaved and matched comparator cohorts presented in this table were calculated using the full 
cohort only. For chronic urticaria, the total number of bereaved and comparison persons was 144,748 and 1,207,774 respectively in the UK and 316,437 and 3,003,175 
respectively in Denmark, after excluding those with missing values. For alopecia areata, the total number of bereaved and comparison persons was 150,072 and 1,298,085 
respectively in the UK and 318,687 and 3,046,279 respectively in Denmark after excluding those with missing values. For vitiligo, the total number of bereaved and comparison 
persons was 151,293 and 1,319,143 respectively in the UK and 318,706 and 3,046,587 respectively in Denmark after excluding those with missing values. 
cIn accordance with the confidentiality rules of the CPRD/Danish registries, we have not presented results where numbers of events are less than five.  
 
